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Recent studies suggest that Stat3, a transcription factor that
mediates cytokine signaling, plays a critical role in the
pathogenesis of diabetic nephropathy. Complete Stat3 gene
knockout is embryonic lethal; therefore, we crossed Stat3þ /
mice with Stat3 mutant mice (SA/SA) that lack full Stat3
activity. This strategy generated Stat3SA/ mice (25%
activity) and Stat3SA/þ mice (75% activity), which were
made diabetic using streptozotocin in order to define the
role of Stat3 in diabetic kidney disease. While the glomerular
number was not different between these two groups of mice,
the diabetic SA/ mice had significantly less proteinuria,
mesangial expansion, glomerular cell proliferation, and
macrophage infiltration than the diabetic SA/þ mice. The
reduction in Stat3 activity did not affect glomerular
hyperfiltration seen after the induction of diabetes, as it was
increased to the same degree in both groups of mice.
Phosphorylation of Stat3 was markedly increased in the
glomeruli of diabetic SA/þ mice compared to diabetic
SA/ mice. The expression of inflammatory markers, IL-6,
MCP-1, and activated NF-jB; type IV collagen, TGF-b, and
ICAM-1 mRNA; or type IV collagen and TGF-b protein, were all
found to be significantly less in glomeruli isolated from
diabetic SA/ mice, as compared with diabetic SA/þ mice.
Our study shows that Stat3 plays a critical role in the
regulation of inflammation and abnormal matrix synthesis at
an early stage of DN.
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Diabetic nephropathy (DN) is the leading cause of end-stage
renal disease in the United States.1 Although our under-
standing of the disease pathogenesis is expanding, specific
therapy for DN is still missing. The kidney in diabetes is
exposed to a milieu of high serum glucose, oxidant stress,
and advanced glycation end products (AGE), all of
which contribute to the development of nephropathy. At
the cellular level, this leads to mesangial cell activation,
podocyte apoptosis, and epithelial-mesenchymal transition
of renal tubular epithelial cell.2,3 Inflammatory cell infiltra-
tion into the kidney also plays a critical role in the
pathogenesis of DN.4
Multiple cell signaling pathways, including MAPK, PKC,
and Smad, are activated in the diabetic kidney.2 Several recent
studies suggest that activation of the Janus kinase/signal
transducers and activator of transcription (JAK/STAT) path-
way is also important. A recent study suggests that a
haplotype of interleukin 6 (IL-6), a classic upstream activator
of the JAK/Stat3 pathway, is associated with reduced
glomerular filtration rate (GFR) in type 2 diabetic patients.5
Furthermore, microarray analysis of gene expression in
kidneys of diabetic patients showed that multiple genes in
the JAK/Stat pathways were highly upregulated in glomeruli
at the early stage of DN and in tubular area at the later stage
of disease.6 Angiotensin II has been shown to induce the
phosphorylation and activation of JAK2, STAT1, and STAT3,
which are critical for angiotensin-II-induced proliferation of
glomerular mesangial cells and the production of transform-
ing growth factor-b (TGF-b), collagen IV, and fibronectin
(reviewed by Marrero et al.7). Hyperglycemia is also known
to activate the JAK/STAT pathway in mesangial cells,
presumably due to hyperglycemia-mediated increase in the
production of reactive oxidant species.8 However, the specific
role of Stat in the development and progression of DN has
never been confirmed in vivo using a gene knockout
approach.
There are seven mammalian STAT proteins.9 STAT3 is a
known transducer of signals from IL-6, which is a proin-
flammatory cytokine thought to have a culprit role in the
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development of diabetic complications including DN.10–12
Therefore, we decided to examine the role of STAT3 in the
DN. STAT3 is the only member of the STAT family that leads
to embryonic lethality when deleted.13 To study the role of
STAT3 in DN, we generated transgenic animals with reduced
STAT3 activity (SA/þ and SA/) and characterized the renal
findings of these animals with streptozotocin (STZ)-induced
diabetes mellitus.
RESULTS
Transgenic mice with reduced STAT3 activity
Mice with a homozygous serine to alanine mutation in the 727
residue (SA/SA) were described earlier.14 SA/SA mice have
approximately 50% of the STAT3 activity of wild-type mice. SA/
SA mice were crossed with heterozygous STAT3 knockout mice
(Stat3þ /) to generate SA/þ and SA/ mice with 75 and
25% STAT3 activity, respectively. Mice with more than 50%
Stat3 transcriptional activity have normal phenotypes, whereas
SA/ mice have a lower initial body and kidney weight.15
Induction of diabetes increases Stat3 phosphorylation
The kidney sections were obtained for immunostaining to
confirm the reduction in Stat3 expression in SA/ as
compared with SA/þ mice (Figure 1a). Diabetic SA/þ
mice demonstrated significantly increased Stat3 phosphor-
ylation as compared with non-diabetic SA/þ mice
(Figure 1a). Staining of phosphorylated Stat3 (p-Stat3)
localized predominantly to glomerular cells. Staining of
p-Stat3 was not increased in diabetic SA/ mice. These
findings were also confirmed in isolated glomeruli by
Western blot analysis. As shown in Figure 1b, total Stat3
expression was reduced in both diabetic and non-diabetic
SA/ mice as compared with SA/þ mice. Furthermore,
an increase of p-Stat3 was observed in glomeruli of diabetic
SA/þ mice as compared with non-diabetic SA/þ mice.
However, no change in Stat3 phosphorylation was observed
in glomeruli of SA/ mice with or without diabetes.
Stat3 deficiency prevented diabetes-induced increase in
kidney-to-body weight ratio and albumin excretion
Data on mouse body and kidney weights, blood glucose and
urine albumin/creatinine ratio were summarized in Table 1.
Consistent with earlier studies, SA/ mice were significantly
smaller than SA/þ mice and kidney size was also smaller in
SA/ mice, although there was no significant difference in
kidney-to-body weight ratio between non-diabetic SA/ and
SA/þ mice. To determine whether the reduced kidney
weight in SA/ mice was due to a reduction in nephron
number, we determined the total glomerular number of
SA/ and SA/þ mice. We did not find a significant difference
in the total number of glomeruli between SA/ and SA/þ
mice (16,306±1096 vs 15,896±1120, respectively, P40.05).
Induction of diabetes did not alter the body weight of either
SA/þ or SA/ mice significantly. However, kidney-to-body
weight ratio was increased in diabetic SA/þ mice as compared
with non-diabetic SA/þ mice, whereas no significant increase
in kidney-to-body weight ratio was observed between
diabetic and non-diabetic SA/ mice. This suggests that
diabetes-induced kidney hypertrophy was prevented in
diabetic SA/ mice. Diabetic SA/ mice developed
significantly less albuminuria than diabetic SA/þ mice.
Blood glucose levels did not differ between diabetic SA/þ
and diabetic SA/ mice.
Stat3 deficiency reduced glomerular volume and mesangial
expansion in diabetes
Diabetic SA/þ mice had increased glomerular volume and
developed significant mesangial expansion as characterized
by increased mesangial/glomerular area fraction (Figure 2a
and b). However, diabetic SA/ mice did not have
significantly increased glomerular volume and mesangial/
glomerular fraction as compared with non-diabetic SA/
mice (Figure 2a and b). Non-diabetic SA/ and SA/þ mice
did not differ significantly. The smaller glomerular volume of
non-diabetic SA/ as compared with non-diabetic SA/þ
mice suggests that the smaller average kidney size of SA/
mice is most likely due to a reduction in nephron size.
Reduction in Stat3 activity does not prevent diabetes-
induced glomerular hyperfiltration in SA/ mice
Glomerular filtration rate was determined by the measure-
ment of fluorescein isothiocyanate (FITC)-inulin clearance
before and after the induction of diabetes in SA/þ and SA/
mice. We found that the induction of diabetes increased GFR
to the same extent in both SA/þ and SA/ mice (SA/þ :
201±28, diabetic SA/þ : *253±34, SA/: 198±25, diabetic
SA/: *246±34, *Po0.05 as compared with non-diabetic
mice, n¼ 6). These data suggest that reduction of Stat3
activity in SA/ mice prevented the early diabetic kidney
disease without affecting glomerular hyperfiltration. Mice
with myeloid cell-specific deficiency of Stat3 are known to
develop diarrhea due to spontaneous colitis.16 However, we
did not observe any diarrhea in our SA/ mice, which is
most likely due to the fact that our SA/ mice preserved a
baseline Stat3 activity (25%), and the mice with myeloid cell-
specific deficiency of Stat3 have a completely absence of Stat3
expression. We also measured urinary osmolarity randomly
in SA/þ and SA/ mice as a surrogate marker of volume
status to ensure that SA/ mice were not hypovolemic. We
did not find any difference between the urine osmolarity of
SA/þ and SA/ mice (1023±112 vs 987±84 mOsm/kg,
n¼ 6).
Reduction of Stat3 reduces glomerular type IV collagen
accumulation and TGF-b expression
To further examine the development of histological changes
in SA/þ and SA/ mice with diabetes, we examined the
molecular pathology that is classically associated with DN. As
it has been shown earlier that Stat3 mediated hyperglycemia-
induced type IV collagen and TGF-b expression in mesangial
cells in vitro,17 we determined the glomerular expression of
type IV collagen and TGF-b in SA/þ and SA/ mice with
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and without STZ-induced diabetes. Diabetic SA/þ mice had
significantly more glomerular expression of type IV collagen
and TGF-b as compared with diabetic SA/ mice (Figure 3
and Table 2). As immunostaining is a semiquantitative assay,
we confirmed these findings by quantitative real-time PCR of
RNA extracted from isolated glomeruli. As expected, we
found that the expression of type IV collagen and TGF-b was
significantly attenuated in diabetic SA/ mice as compared
with diabetic SA/þ mice (Figure 4).
Stat3 reduction prevented mesangial cell proliferation in
diabetes
We also examined the expression of Ki67 as a marker for cell
proliferation. Diabetic SA/þ mice had increased Ki67
staining following a mesangial distribution. However, this
increase in Ki67 expression was not seen in diabetic SA/
mice, indicating that Stat3 mediated diabetes-induced
mesangial cell proliferation (Figure 5 and Table 2).
Reduction of Stat3 reduced macrophage infiltration in
diabetes
As Stat3 is known to mediate inflammatory response, we also
examined the expression of CD68, a macrophage marker. We
found that CD68 expression was increased in diabetic SA/þ
mice as compared with non-diabetic SA/þ , but absent in
diabetic SA/ mice. This suggested that a reduction in Stat3
activity prevented macrophage infiltration in diabetes (Figure 5
and Table 2). Furthermore, the expression of intercellular
adhesion molecule-1 (ICAM-1), a monocyte-macrophage in-
filtration marker,18 was also found to be suppressed in diabetic
SA/ mice as compared with diabetic SA/ mice (Figure 4).
Expression of IL-6 and MCP-1 was reduced in diabetic
SA/ mice
As our data suggested a role of Stat3 in mediating the
inflammatory response in the diabetic kidney, we examined
the expression of IL-6 and MCP-1 in the glomeruli of these
T-Stat3
a
b
p-Stat3
T-Stat3
p-Stat3
β-Actin
SA/− SA/− DM SA/+ SA/+ DM
SA/− SA/− DM SA/+ SA/+ DM
Figure 1 | Phosphorylation of Stat3 in the kidney. (a) Immunostaining of total and phosphorylated Stat3 in kidney sections.
Immunohistochemistry was performed on paraffin sections of kidneys from SA/þ and SA/ mice with and without STZ-induced diabetes
(SA/þ , SA/þ DM, SA/, and SA/ DM) using rabbit polyclonal anti-total Stat3 (T-Stat3) and anti-phospho-Stat3 antibodies (p-Stat3).
The staining for T-Stat3 in SA/þ was more than in SA/ mice. Representative immunostaining results are shown. (b) Western blot of T-Stat3
and p-Stat3 in isolated glomeruli. Isolated glomeruli from diabetic and non-diabetic SA/ and SA/þ mice were lysed in lysis buffer
containing protease and phosphatase inhibitors. Western blot was performed using anti-total Stat3, anti-phospho-Stat3 (Cell Signaling
Technology), and anti-b-actin (Sigma) antibodies. Representative blots of three independent experiments are shown.
Table 1 | Characteristics of mice
BW (g) KW (mg) KW/BW (mg/g) Serum glucose Urine albumin/creatinine
SA/+ 25.2±2.9 222±36 8.9±1.2 175±18 0.08±0.07
SA/+ DM 24.2±3.8 243±45** 10.1±0.8** 404±89 0.31±0.10
SA/ 21.4±0.9+ 190±35+ 9.1±0.86 164±12 0.08±0.09
SA/ DM 20.1±0.8 193±13 9.6±1.41 393±42 0.12±0.10*
BW, body weight; KW, kidney weight; KW/BW, kidney-to-body weight ratio.
Characteristics of mice: mouse body weight, kidney weight, serum glucose, and urinary protein excretion (urine albumin/creatinine ratio) are summarized.
N=6, *Po0.05 as compared with SA/+ with DM (SA+DM), **Po0.05 as compared with SA/+ mice, +Po0.05 as compared with SA/+.
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mice. We found that IL-6 and MCP-1 mRNA expression was
increased in diabetic SA/þ mice as compared with non-
diabetic SA/þ (Figure 6a and b). However, no significant
change in the expression of MCP-1 and IL-6 was observed
between diabetic SA/ and non-diabetic SA/ mice. As it is
known that Stat3 interacts with the nuclear factor (NF)-kB
pathway,19,20 we assessed NF-kB activity in kidneys of these
mice by determining its expression in the cytoplasm and
nucleus. By Western blotting (Figure 6c), we found that the
expression of NF-kB increased significantly in the cytosolic
fraction of the glomerular lysates from both diabetic SA/þ
and SA/ mice as compared with their non-diabetic
counterparts. However, a marked increase in NF-kB was
observed in diabetic SA/þ mice but not in diabetic SA/
mice. These data demonstrate that STZ-induced diabetes
increases the expression of NF-kB, which is independent of
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Figure 2 | Analysis of kidney histology. (a) Kidney histology. Periodic acid-Schiff (PAS) staining was performed in kidneys of SA/þ
and SA/ mice with or without diabetes (SA/þ , SA/þ DM, SA/, and SA/ DM). An increase in mesangial area was observed in SA/þ
DM mice as compared with SA/ DM mice. Representative pictures are shown here. (b) Morphometric analysis of glomerular volume and
PAS-positive area was performed in kidney sections of all mice. The glomerular volume and mesangial area per glomerular cross-section
area (% of mesangial fraction) is shown (n¼ 6, *Po0.01 compared with SA/þ , **P40.05 compared with SA/, þPo0.05 compared with
SA/þ , and þ þPo0.05 compared with SA/þ DM).
Type IV
collagen
TGF-β
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Figure 3 | Immunostaining of type IV collagen and TGF-b in kidneys of mice. Immunohistochemistry was performed in paraffin
sections of kidneys from diabetic and non-diabetic SA/þ and SA/ mice using anti-type IV collagen and anti-TGF-b antibodies. There are
significant increases in type IV collagen and TGF-b expression in SA/þ DM mice compared with SA/ DM mice. The representative pictures
are shown here. Rabbit IgG was used as a negative control. Semiquantification of intensity of staining is summarized in Table 2.
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Stat3 activity. However, a reduction of Stat3 activity is
associated with a decrease in NF-kB nuclear shuttling and
presumably its activation. cAMP response element binding
and b-actin were used here as the loading controls for nuclear
and cytosolic proteins, respectively.
DISCUSSION
Multiple in vitro studies have suggested that Stat3 is an
important mediator of DN pathogenesis. In this study, we
demonstrate a significant role for Stat3 in the development of
DN in vivo. Although SA/þ and SA/ mice developed
similar degrees of hyperglycemia during the study, SA/ mice
were less susceptible to the development of proteinuria and
pathological changes associated with DN.
In our study, SA/þ (75%) and SA/ (25%) littermates
were used for comparison, because it has been shown
previously that a reduction in Stat3 activity to 25% causes
phenotypic changes.15 In a preliminary study, we compared
the severity of DN between SA/þ and wild-type mice and
did not find any difference in proteinuria and mesangial
expansion (data not shown). SA/ mice are known to have
lower body and kidney weight. Our findings suggest that the
number of glomeruli did not differ between SA/þ and SA/
mice. Therefore, the reduction in kidney weight is most likely
due to a reduction in nephron size.
Table 2 | Semiquantitative assessment of staining
Type IV collagen (%) TGF-b (%) Ki67 CD68
SA/+ 7.8±1.3 4.4±1.1 1.34±2.46 0.35±0.50
SA/+ DM 26.2±3.2 15.3±3.5 7.87±2.52 3.55±0.68
SA/ 8.2±1.4 5.1±1.6 1.25±1.56 0.18±0.12
SA/ DM 9.3±2.4* 5.5±1.2* 3.00±0.36* 0.52±0.11*
TGF-b, transforming growth factor-b.
Semiquantitative assessment of staining: intensity of immunostaining was
quantified as described in the Materials and Methods section. For type IV collagen
and TGF-b, % of positive staining area per glomerular cross-section was measured
by MetaMorph software. For Ki67 and CD68, number of positive cells per glomerular
cross-section was counted.
N=6, *Po0.01 as compared with SA/+ DM.
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Figure 4 | Real-time PCR for type IV collagen, TGF-b, and ICAM-1. Total RNA was extracted from the glomerular isolates. Real-time
PCR was performed as described in the Materials and Methods. The ratio of type IV collagen, TGF-b, and ICAM-1 to tubulin mRNA levels
was obtained and the fold of change for each as compared to the pooled glomeruli from wild-type (WT) mice is shown. *Po0.05 compared
with SA/þ and SA/ DM mice, n¼ 6.
Ki67
SA/+ SA/+ DM SA/– SA/– DM
CD68
Figure 5 | Immunostaining of Ki67 and CD68 in kidneys of mice. Immunohistochemistry was performed in paraffin sections of kidneys
from diabetic and non-diabetic SA/þ and SA/ mice using anti-Ki67 and anti-CD68 antibodies. There is a significant increase of Ki67
and CD68 staining in kidneys of SA/þ DM mice as compared with SA/ DM mice. Semiquantitative measurement of the staining intensity
is summarized in Table 2.
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Earlier studies reported that mice with myeloid cell-
specific deletion of Stat3 developed spontaneous colitis.16
However, our SA/ mice with 25% of Stat3 activity did not
have any watery stools. To rule out volume depletion in SA/
mice, urinary osmolarity was determined and no difference
was observed between SA/þ and SA/ mice. Furthermore,
we confirmed that both SA/þ and SA/ mice developed
similar degree of hyperfiltration at the early stage of DN.
Therefore, reduction of Stat3 activity to 25% did not prevent
the development of hyperfiltration at the early stage of
diabetes in SA/ mice.
Of interest, Stat3 is a known mediator of insulin-like
growth factor 1 (IGF-1) signaling.21 Earlier studies indicate
that SA/ mice have decreased circulating levels of IGF-1,15
which may contribute to the small body and kidney size.
IGF-1 has been implicated in the pathogenesis of DN.22 It has
been also shown that dwarf mice are protected from DN.23
The reduction in IGF-1 level and body weight are potential
confounders for the development of DN. In future studies,
we will need to delineate the relative contribution of reduced
IGF-1 level and small body weight to the protection of DN in
SA/ mice. To address this issue, we are developing a
podocyte-specific Stat3 knockout mice, in which Stat3
activity will be reduced only in podocytes.
Earlier in vitro studies suggest that JAK/Stat3 plays an
important role in the pathogenesis of DN.7 Stat3 is activated
by many components of the diabetic milieu, including high
glucose, reactive oxygen species, AGE, and angiotensin II in
primarily, in mesangial cells.24–26 Both angiotensin-convert-
ing enzyme inhibitor and angiotensin II receptor blockade
prevent hyperglycemia-induced activation of JAK-Stat acti-
vation in diabetic kidney glomeruli.25 Reactive oxygen species
plays a critical role in the pathogenesis of DN. It is well
known that reactive oxygen species activate the Stat3
pathway. Recently, it has been shown that antioxidants
inhibit hyperglycemia-induced Stat3 activation.27 Selective
inhibitor of JAK2 (AG490) ameliorates nephrotic syndrome
in adriamycin-induced nephropathy, suggesting that Stat3
plays a role in podocyte injury, which is presumably due to
reactive oxygen species-induced Stat3 activation.28 The AGE
and receptor for AGE (RAGE) interaction plays a key role in
the pathogenesis of DN. It has been shown that Stat3 also
mediates RAGE-mediated collagen synthesis.24 Furthermore,
simvastatin, which has been shown to improve diabetic
kidney disease, also attenuates high glucose and angiotensin
II-induced Stat3 activation.29
Stat3 also plays an important role in other kidney diseases
including Thy-1 glomerulonephritis model,30 Gas6 nephro-
pathy,31 and HIV-associated nephropathy.32 Stat3 has also
been shown to mediate hypoxia-induced vascular endothelial
growth factor synthesis in renal carcinoma cells.33 In
addition, many studies suggest that Stat3 plays an important
role in acute kidney injury mediating apoptosis, epithelial-
mesenchymal transitions, and inflammation in renal tubular
epithelial cells.34
This is the first study to examine the role of Stat3 in DN
in vivo using a knockdown animal model (75% reduction of
Stat3 activity). We believe this knockdown model is better
than the knockout system because a basal activity of most
signaling molecules is required for normal biological function
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Figure 6 | Analysis of inflammatory markers in the kidneys. (a and b) Real-time PCR for MCP-1 and IL-6: total RNA was isolated
from glomeruli of these mice. Real-time PCR was performed as described in the Material and Methods section. The ratio of MCP-1 and IL-6
to tubulin mRNA levels was obtained and the fold of change for each as compared to the pooled glomeruli from wild-type (WT) mice is
shown. *Po0.05 compared with SA/þ and SA/ DM mice, n¼ 6. (c) Western blot of p65-NF-kB: both cytosolic and nuclear proteins were
isolated as described. Western blot was performed using rabbit anti-p65-NF-kB antibody, anti-CREB (loading control of nuclear protein), and
anti-b-actin (loading control of cytosolic protein) antibodies. Representative blots of four independent experiments are shown.
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of cells. Consistent with previous findings,7 we found that
diabetes-induced mesangial cell proliferation, TGF-b expres-
sion, and abnormal type IV collagen synthesis were
significantly inhibited in SA/ mice, indicating that Stat3
plays a role in the regulation of extracellular matrix synthesis.
Interestingly, we found that infiltration of inflammatory
cells was also significantly reduced in SA/ mice. Consistent
with our findings, it has been shown that inhibition of the
JAK/Stat3 pathway reduces infiltration of interstitial inflam-
matory cells and production of chemokines in the adriamy-
cin-induced nephropathy model.28 Furthermore, we found
that a reduction of Stat3 activity abrogated the stimulation of
proinflammatory markers, including IL-6, ICAM-1, and
MCP-1, and blocked nuclear translocation of NF-kB. IL-6
is a well-known proinflammatory cytokine that is activated
through the Stat3 pathway.4 Recent studies suggest that an
IL-6 haplotype is associated with impaired renal function in
type 2 diabetic patients.5 MCP-1 and ICAM-1 are known to
cause infiltration of inflammatory cells in the diabetic
kidney.4 Knockout of either MCP-1 or ICAM-1 prevents
kidney disease in diabetic animal models.35,36 Earlier studies
suggest that NF-kB and its target genes, including IL-6 and
MCP-1, are activated in diabetic kidney.4,37,38 Stat3 is known
to cross-talk and activate NF-kB.19,20 NF-kB expression is
known to be increased in the diabetic condition,39 which is
consistent with our finding of increased NF-kB expression
in the cytosolic fraction of glomerular lysates from diabetic
SA/þ and SA/ mice as compared with their non-diabetic
counterparts. In addition, we also observed that Stat3
mediates diabetes-induced translocation of NF-kB in glo-
merular cells. On the basis of these findings, we believe that
Stat3 mediates inflammatory response either directly by
stimulating its target genes, such as ICAM-1, or indirectly
through the activation of NF-kB leading to MCP-1 and IL-6
production. This increase in IL-6 production could then
further stimulate the Stat3 pathway resulting in a vicious
cycle of escalating inflammation and inflammatory response
in the diabetic milieu. Therefore, we believe that Stat3
mediates both fibrosis, through the TGF-b pathway, and
inflammatory pathways in diabetic kidney; however, this will
need to be further confirmed in the future.
A limitation of our study is that Stat3 is ubiquitously
expressed and the reduction of Stat3 activity in our animal
model occurs in all tissues expressing Stat3. Therefore, our
study does not address the relative contribution of Stat3
inactivation in renal cells versus systemic effects. Diabetes-
induced Stat3 activation in podocytes and glomerular
endothelial cells has not been carefully examined in the past.
Earlier studies have focused on the role of Stat3 signaling in
mesangial cells.7 Our studies suggest that an increase in Stat3
phosphorylation is localized predominantly to the glomeru-
lar region of mice with early DN. Although we did not
perform colocalization studies, our immunostaining data
showed that Stat3 phosphorylation seems to occur mostly in
podocytes. However, our studies suggest that the reduction of
Stat3 activity prevents diabetes-induced mesangial activation
and abnormal matrix synthesis. Further studies are required to
confirm the cellular localization of pStat3 and to investigate
whether and how podocytes cross-talk with mesangial cells
through Stat3 activation. We propose that hyperglycemia, AGE,
and/or angiotensin II may activate the Stat3 pathway in
podocytes, thus promoting the synthesis and the secretion of
growth factors and cytokines such as TGF-b and IL-6. These
growth factors and cytokines could act on the surrounding
mesangial cells in a paracrine manner to activate the synthesis of
abnormal matrix by mesangial cells.
Another limitation of the study is that these mice did not
develop significant glomerulosclerosis as seen in human DN
most likely due to the genetic background of the experi-
mental animal and the duration of diabetes in the study. To
further confirm the results of our study, the role of Stat3
needs to be determined in these animals with longer duration
of diabetes as well as in other animal models of DN. Future
studies are also required to determine whether inhibition of
JAK/Stat3 pathway could be a novel target of therapy for DN.
MATERIALS AND METHODS
Experimental design
All mice are in C57BL/6 background. Genotyping by PCR was
performed at 3 weeks of age as described earlier.15 SA/þ and SA/
mice (six mice of each genotype) at 6 weeks of age were injected
with 5 serial doses of STZ (50 mg/kg) or vehicle as described by the
Animal Models of Diabetic Complications Consortium with one
modification: instead of 5 consecutive injections, animals were
injected on alternating days without fasting before injection.
Unrestricted food and water were provided throughout the duration
of the experiment. Serum glucose was monitored every 2–3 days.
Diabetes was defined as a blood glucose level above 300 mg per
100 ml. All mice developed diabetes at 8–10 weeks of age and were
killed at 4–5 months of age for tissue collection after 8 weeks of
hyperglycemia. Blood and urine samples were collected at the end of
studies. Body and kidney weight was recorded. Studies were
performed according to the protocols approved by the Institutional
Animal Care and Use Committee. Of note, wild-type mice were also
rendered diabetic with STZ. However, there was no significant
difference in the amount of proteinuria or glomerular/mesangial
area fraction between SA/þ and wild-type mice with diabetes.
Therefore, we used SA/þ mice as controls for SA/ mice in the
study.
Histology
Mice were perfused with phosphate-buffered solution and the
kidneys were fixed in 4% paraformaldehyde for 2 h. The kidneys
were paraffin embedded by American Histolabs Inc. (Gaithersberg,
MD, USA). The kidney histology was examined after periodic acid-
Schiff staining.
Measurement of urine albumin and creatinine
Urine albumin concentration was measured following the manu-
facturer’s protocol (Mouse Albumin ELISA Quantitation Kit, Bethyl
Laboratory Inc., Houston, TX, USA). Urine creatinine concentration
was measured using an assay based on the Jaffe’s reaction according
to the manufacturer’s protocol (Creatinine Assay Kit, Cayman
Chemical Company, Ann Arbor, MI, USA). The amount of urine
albumin excretion was expressed as a ratio of albumin to creatinine.
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Glomerular count
The glomerular number was determined as described earlier.40
Briefly, kidneys were decapsulated, cut into 2 mm pieces, and
incubated in 5 ml of 6 N HCL at 371C for 90 min. The resultant
suspension was diluted to 30 ml of sterile water and allowed to stand
overnight at 41C. The glomerular number was counted in triplicate
under a phase microscope using a counting chamber.
Quantifying mesangial expansion
Glomerular volume and mesangial area were determined by
examining plastic-embedded sections using a digitizing tablet and
video as described earlier.41 The relative mesangial area was
expressed as mesangial/glomerular surface area (%).
Immunohistochemistry
The paraffin-embedded kidney sections from SA/þ and SA/ mice
were prepared in identical manner. Immunostaining was performed
using anti-total or phospho-Stat3 (Cell Signaling Technology,
Danvers, MA, USA), anti-type IV collagen or anti-Ki67 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), anti-CD68 (R&D
Systems, Minneapolis, MN, USA), and biotinylated secondary
antibodies (Vector Laboratories, Burlingame, CA, USA). Slides were
mounted with Aqua Poly/Mount (Polysciences Inc., Burlingame, CA,
USA) and photographed under an Olympus BX60 microscope
(Olympus Optical Co, Center Valley, PA, USA) with a digital camera.
Quantitative analyses of type IV collagen and TGF-b expression in
glomerular area were performed using a quantitative image anal-
ysis system (Metamorph, Sunnyvale, CA, USA). Twenty random
glomerular cross-sections (40 power) were chosen from each
tissue section and examined. The examined area was outlined, the
positive staining patterns were identified, and the percent positive
staining area per glomerular cross-section was then measured. For
Ki67 and CD68 staining, the number of positive cells per glomerular
cross-section area in kidney sections was counted as described
earlier.32 The data were presented as the number of positive cells per
glomerulus per cross-section. Positive was defined as a cell that had
obvious changes of intensity above baseline levels. Two investigators
blinded to the samples quantified the staining independently.
Western blot
Glomeruli were isolated from the kidney cortex of these mice after
perfusion witho5 mm iron oxide solution as described earlier42 and
lysed with a buffer containing 1% Triton, a protease inhibitor
cocktail and tyrosine, and serine-threonine phosphorylation in-
hibitors. To determine NF-kB activity, both nuclear and cytosolic
proteins were isolated from glomeruli. Cell lysates were analyzed by
SDS-polyacrylamide gel electrophoresis and immunoblotted using
anti-phospho-Stat3 and anti-total Stat3 antibodies, anti-p65 NF-kB
(Santa Cruz), anti-CREB (Cell Signaling Technology), and anti-b-
actin antibody (Sigma, St Louis, MO, USA).
Real-time PCR
Total RNA was isolated from glomeruli of these mice using TRIzol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. Quantitative real-time PCR was performed using a Roche
Lightcycler and the Qiagen QuantiTect One Step RT-PCR SYBR
green kit (Qiagen, Valencia, CA, USA) according to the manu-
facturer’s protocol. Pre-designed primer sets were purchased from
Qiagen, GeneGlobe for type IV collagen, TGF-b, ICAM-1, IL-6,
and MCP-1. The following primer pair was used for tubulin:
50-TGCCTTTGTGCACTGGTATG-30 and 50-CTGGAGCAGTTTGA
CGACAC-30. LightCycler analysis software was used to determine
crossing points based on the second derivative method. Data were
normalized to tubulin expression and presented as fold increase
relative to RNA isolated from pooled normal glomeruli of wild-type
mice using the 2DDCT method.
Measurement of GFR by single bolus injection of FITC-inulin
Diabetes was induced at the age of 6 weeks by injection of STZ in both
SA/þ and SA/ mice. FITC-inulin clearance was measured 6 weeks
after the onset of diabetes as described.43 Briefly, dialyzed FITC-inulin
(3.74ml/g body weight) was injected retroorbitally under light
anesthesia with isoflurane (Baxter Pharmaceutical Products, Deerfield,
IL, USA). Approximately 20ml of blood were collected through the tail
vein at 3, 7, 10, 15, 35, 55, and 75 min post-injection of FITC-inulin,
yielding 10ml of plasma for the determination of FITC-inulin
concentration by measurement of fluorescence. Two-compartment
clearance models were used for the calculation of GFR.
Measurement of urinary osmolarity
Fresh urine samples were collected in the tubes and immediately sealed
with parafilm. Urinary osmolarity was determined using the Wescore
Vapro Osmometer. All samples were measured in triplicates.
Statistical analysis
Data were expressed as mean±s.d. (X±s.d.). The unpaired t-test
was used to analyze the data. Statistical significance will be
considered when Po0.05.
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